ImpactWayv™ Launches Social Media Platform Focused on Social Good
15.6.2021 16:00:00 EEST | Business Wire | Press release
ImpactWayv, Inc. today announced the public launch of its pioneering social media platform, ImpactWayv™, which is now available to download on the Apple App Store. The new platform’s focus is to connect people, businesses and philanthropy for social good.
Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv was created to drive collective impact across causes and communities. The platform operates as an entirely new kind of digital ecosystem, enabling users to effect, engage in and share social impact on a global scale.
Users of ImpactWayv will be able to connect and interact with each other through each of its core components, including:
- Public and private personal networks and content feeds to engage with and create impact.
- The “Impact Market” – a public exchange of transparent impact profiles of businesses and nonprofits for all to compare, follow, engage with and directly support.
- “Wayvs” (social impact causes, topics, trends and broader issue areas) – an organizing framework for purpose-driven content and information across the platform.
“ImpactWayv is democratizing social impact for all,” said Dan Rubino, Co-Founder, Chairman and Chief Executive Officer of ImpactWayv, Inc. “Finally, there is a purpose-built social media platform that gives consumers, brands, businesses and nonprofits a way to explore, create, engage and transact across all categories of daily life, with more meaning, more purpose and more goodwill.”
Engagement on the platform is driven by dozens of Wayvs™ ranging across social impact cause areas and covering various topics relating to the interplay of business, philanthropy and individual effort to drive social good. Some examples include Climate Action; Diversity, Equity and Inclusion (DE&I); Corporate Social Responsibility (CSR); Human Rights; Public Health; Environmental, Social and Governance (ESG); Voter Registration; and Renewable Energy. Wayvs facilitate and encourage user discoverability and engagement across the platform. Users tap them to find relevant impact discussions and initiatives, as well as like-minded individuals, companies and nonprofits that share their commitment to the causes they care about.
“An unprecedented interest in social action has been building globally for some time, further accelerated and focused by recent events,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “People need a way to explore and express their values. Businesses need to use their resources and influence to make things better. And nonprofits need to leverage their missions for maximum effectiveness. ImpactWayv meets this unique moment in time by linking people and organizations around the world on a deeper level.”
To catalyze user engagement, ImpactWayv also created a groundbreaking tool to measure a user’s impact on their digital community, through the platform’s signature “Impact” metric, which tracks a user’s positive “ripple effect” across the platform, in real time.
“Our ambition at ImpactWayv is to disrupt and transform the worlds of business and philanthropy through technology,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “Through our extraordinary blend of seasoned leaders and trailblazers in the worlds of corporate purpose, philanthropy and technology, we believe we have created a powerful business model that will advance universal social good.”
ImpactWayv is now available for free download on the Apple App Store and will be available on Google Play and other non-iOS devices later this year. Companies and nonprofits are also invited to contact ImpactWayv to become a member of the platform, which will enable them to claim their profile, initiate an engagement strategy on ImpactWayv and become a “Featured Organization” on the platform.
About ImpactWayv, Inc.
ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information, please visit: www.impactwayv.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005331/en/
Contact information
Media
Jonathan Younger
214-259-3426
jonathan.younger@ketchum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
